Supraventricular tachycardia treatment drugs
Pro Research Analysisby 
Searched over 200M research papers
Acute Drug Treatment for Supraventricular Tachycardia (SVT)
Adenosine is widely recognized as the first-line drug for the acute treatment of paroxysmal supraventricular tachycardia (PSVT) in both adults and children. It works by causing a temporary block in the atrioventricular (AV) node, which can quickly restore normal heart rhythm in most cases. Adenosine is highly effective, with success rates reported around 93% in adults and high efficacy in pediatric populations as well. Its action is very brief, and while it often causes short-lived side effects like chest discomfort, flushing, or shortness of breath, serious adverse effects are rare. Adenosine is especially preferred when the diagnosis is uncertain or when other drugs like verapamil may be risky, such as in patients with heart failure or wide-complex tachycardia 1234+2 MORE.
If adenosine is not effective or cannot be used, calcium channel blockers (CCBs) such as verapamil and diltiazem are commonly used alternatives. These drugs are also effective in terminating SVT, but they have a longer duration of action and a different side effect profile. Verapamil, for example, can cause hypotension, especially if given rapidly or in patients with underlying heart disease. Both adenosine and CCBs have similar efficacy, but adenosine acts faster and is generally considered safer, though it is more expensive and has a higher chance of arrhythmia recurrence shortly after administration 256.
Chronic and Maintenance Drug Therapy for SVT
For long-term prevention of SVT recurrences, several drug classes are used depending on the type of SVT and patient characteristics. Beta-blockers and calcium channel blockers are often chosen for maintenance therapy, especially in pediatric patients. In cases where these are not effective, sodium channel blockers such as flecainide or propafenone may be considered. Potassium channel blockers like sotalol or amiodarone are alternatives, particularly in drug-resistant cases 35910.
In neonates and infants, propranolol is the most commonly used maintenance drug, followed by amiodarone and flecainide. Sometimes, a combination of medications is required to control the arrhythmia, especially in cases that do not respond to a single drug. Most neonatal SVT resolves within the first year of life, so maintenance therapy is typically continued until the child is one year old 310.
Special Considerations in Pediatric and Fetal SVT
In pediatric SVT, adenosine remains the first choice for acute management, with CCBs and beta-blockers used for ongoing control. In fetal SVT, flecainide has been shown to be more effective than digoxin, especially in cases complicated by hydrops (fluid accumulation in the fetus). Flecainide, alone or in combination with amiodarone, leads to higher rates of conversion to normal rhythm and better outcomes compared to digoxin 38.
Emerging and Experimental Drug Therapies
Research is ongoing into new drugs for SVT that target specific molecular pathways, such as inflammation and structural remodeling of the heart. These experimental therapies aim to provide more personalized and effective treatment options, especially for patients who cannot undergo catheter ablation or do not respond to conventional drugs .
Conclusion
Adenosine is the preferred first-line drug for acute SVT episodes due to its rapid action and safety profile, with calcium channel blockers as effective alternatives. For chronic management, beta-blockers, calcium channel blockers, and, in some cases, sodium or potassium channel blockers are used. In pediatric and fetal cases, drug choice may differ, with flecainide showing particular benefit in fetal SVT. Ongoing research into new drug therapies may further improve outcomes for patients with SVT 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic